Germany Diabetes Care Devices Market Size
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 2.27 Billion |
| Market Size (2029) | USD 3.05 Billion |
| CAGR (2024 - 2029) | 6.07 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Germany Diabetes Care Devices Market Analysis
The Germany Diabetes Care Devices Market size is estimated at USD 2.27 billion in 2024, and is expected to reach USD 3.05 billion by 2029, growing at a CAGR of 6.07% during the forecast period (2024-2029).
The COVID-19 pandemic highlighted that substantially greater attention had to be given to diabetes to avoid unnecessary and inequitable outcomes from the infection. According to an article titled "Incidence of newly diagnosed diabetes after COVID-19," published in Diabetologia 2022, the human pancreas could also be a target of SARS-CoV-2. Following a COVID-19 infection, reduced insulin secretory granules in beta cells and impaired glucose-stimulated insulin secretion were observed. In addition, after the pandemic, some patients developed insulin resistance and had elevated blood glucose levels, although they had no previous history of diabetes.
Unusually high or low blood glucose levels can potentially lead to acute and or chronic, life-threatening conditions. Managing diabetes to improve patient outcomes requires a complex multidisciplinary approach. Appropriate and timely blood glucose monitoring allows the successful management of out-of-range blood glucose levels, minimizing diabetic-related health complications. Diabetes can be considered a data management disease and an example of real-world health and treatment data acquisition to inform integrated and personalized chronic disease management. Both patients and diabetes care providers continuously collect metabolic, treatment, and lifestyle data in joint decision-making on treatment—digital health technologies, including digital health applications, support diabetes self-management.
The vast range of apps in the diabetes field supports the adoption of lifestyle interventions for the prevention and management of diabetes, the evaluation of blood glucose control quality, and the dosing of insulin. Integrating blood glucose monitoring with insulin calculators, automated insulin titration software, and remote coaching are further developments that provide patients with poorly controlled diabetes additional support needed to improve critical outcomes, enhancing market prospects in future years.
Germany Diabetes Care Devices Market Trends
Rising Diabetes Prevalence in Germany is driving the market in forecast period.
According to the German Diabetes Centre (DDZ), about 8.5 million people in Germany are affected by diabetes. The number of people with Type 2 diabetes in Germany will continue to increase over the next twenty years. Researchers at DDZ estimate that up to twelve million people might suffer from metabolic disorders in 2040.
According to the European Observatory on Health Systems and Policies 2021, Germany has the world's oldest social health insurance (SHI) system. Health insurance is compulsory. People with an income above a fixed threshold or belonging to a particular professional group can opt out of SHI coverage and enroll in private health insurance (PHI). About 11% of the population is covered by PHI and 89 % by SHI. Although coverage is universal for all legal residents, only 0.1% of the population does not have health insurance.
Technological advancements in insulin delivery devices have increased for safer and more accurate insulin administration. In April 2021, Medtronic introduced the Medtronic Extended infusion set in selected European countries as the first and only infusion set that can be worn for up to 7 days. An infusion set is a tubing that delivers insulin from the pump to the body and typically requires a set change every few days. This innovation doubles the length of time an infusion set can be worn so users can safely stay on insulin pump therapy with fewer interruptions and insertions while introducing enhanced convenience and comfort to their diabetes management routine. The set is compatible with all MiniMed 600 and 700 series insulin pumps.
German diabetes patients have some of the lowest out-of-pocket costs in the world, according to T1 International, an advocacy group for people with diabetes. Stringent government policies and favorable regulations by WHO in Germany are encouraging companies to develop innovative products. Penetration of these products in the German market supports local clinical research organizations in their clinical research trials and ensures ease of management, facilitating the discovery process.
Therefore, the market is anticipated to grow over the analysis period due to rising prevalence and the aforementioned factors.
The Self-monitoring Blood Glucose Segment Holds the Highest Market Share in the Current Year
The self-monitoring blood glucose segment occupies the highest market share of about 38.7% in the current year.
Self-monitoring has streamlined regular blood testing to assess one’s diabetes control and inform changes to enhance control. With diabetes being related to the body’s ineffective use of insulin, the disease has a high incidence rate, broad pathogenic factors, various complications, and difficulty in curing and causing other lethal hazards to human health. Traction for easy-to-use blood glucose devices has increased and is essential to prevent or detect hypoglycemia and hyperglycemia. Several technological advances have pushed manufacturers to introduce meters that are less painful and invasive at the time of testing and can provide robust and rapid testing with alternative-site testing and a smaller sample size, thereby enhancing the market prospects in the years to come.
Various innovations in lancing devices offer a convenient way to draw blood samples, such as Accu-Check FastClix, which has a preloaded lancet drum, so a person can load six lancets at a time rather than replacing the lancets after every use. The Accu-Chek FastClix also has a lever and a counter, so the user can easily move to the next lancet and see how many are left in the drum. Accu-Chek states that this model has 11 depth settings. There is also a locking system to prevent lancing accidents. The Accu-Chek FastClix comes with 102 lancets.
Technological advancements in blood glucose meters, including cellular-connected devices that automatically upload SMBG data to secure cloud-based databases, allow for improved sharing and monitoring of SMBG data. Real-time monitoring of SMBG data presents opportunities to provide timely support to patients responding to abnormal SMBG recordings. Such advantages can provide patients with poorly controlled T2D additional support needed to improve critical outcomes, thereby enhancing the market prospects in future years.
Germany Diabetes Care Devices Industry Overview
The German diabetes care devices market is fragmented. Manufacturers have driven constant innovations to compete in the market. The major players, such as Abbott and Medtronic, while adhering to organic growth strategies, are working on various technological advancements, which are evident from the R&D spending of these companies. The manufacturers of insulin delivery devices are spending a massive amount on the R&D of the devices. For instance, in June 2022, Abbott announced that it is developing a new bio-wearable that will continuously monitor glucose and ketone levels in one sensor.
Germany Diabetes Care Devices Market Leaders
-
Abbott Diabetes Care
-
Roche Diabetes Care
-
DexCom Inc.
-
Medtronic PLC
-
Insulet Corporation
*Disclaimer: Major Players sorted in no particular order
Germany Diabetes Care Devices Market News
- October 2022: Medtronic introduced a new program called My Insights, which is exclusively made for individuals using the MiniMed 770G system. Using an individual's data, My Insights relies on the power of data science to provide personalized tips, trends, and reminders that customers can use to help with their diabetes management goals. The My Insights personalized recommendations are shared via a monthly email with educational content that is most relevant based on what an individual may currently be experiencing. This is the first program in diabetes management that goes beyond generalized tips and instead shares personalized suggestions using data from an integrated pump system.
- April 2022: CamDiab and Ypsomed announced the partnership to develop and commercialize an integrated automated insulin delivery (AID) system to help lessen the burden of diabetes management for people with diabetes in European countries. The new integrated AID system is designed to connect Abbott's FreeStyle Libre 3 sensor, the world's smallest and most accurate continuous glucose monitoring sensor, to CamDiab's CamAPS FX mobile app, which connects with Ypsomed's mylife YpsoPump, creating a smart, automated process to deliver insulin based on real-time glucose data. The connected, smart wearable solution is designed to continuously monitor a person's glucose levels and automatically adjust and deliver the right amount of insulin at the right time, removing the guesswork of insulin dosing.
Germany Diabetes Care Devices Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Industry Attractiveness - Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
-
5.1 By Device
- 5.1.1 By Monitoring Devices
- 5.1.1.1 Self-monitoring Blood Glucose
- 5.1.1.1.1 Glucometer Devices
- 5.1.1.1.2 Blood Glucose Test Strips
- 5.1.1.1.3 Lancets
- 5.1.1.2 Continuous Glucose Monitoring
- 5.1.1.2.1 Sensors
- 5.1.1.2.2 Durables
- 5.1.2 By Management Devices
- 5.1.2.1 Insulin Pump
- 5.1.2.1.1 Insulin Pump Device
- 5.1.2.1.2 Insulin Pump Reservoir
- 5.1.2.1.3 Infusion Set
- 5.1.2.2 Insulin Syringes
- 5.1.2.3 Cartridges in Reusable pens
- 5.1.2.4 Insulin Disposable Pens
- 5.1.2.5 Jet Injectors
-
5.2 By End User
- 5.2.1 Hospital/Clinics
- 5.2.2 Personal/Home
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
-
7.1 Company Profiles
- 7.1.1 Abbott Diabetes Care
- 7.1.2 Roche
- 7.1.3 LifeScan
- 7.1.4 Dexcom
- 7.1.5 Medtronic
- 7.1.6 ARKRAY Inc.
- 7.1.7 Ascensia Diabetes Care
- 7.1.8 AgaMatrix
- 7.1.9 Bionime Corporation
- 7.1.10 Novo Nordisk
- 7.1.11 Eli Lilly
- 7.1.12 Sanofi
- 7.1.13 Rossmax International Ltd
- *List Not Exhaustive
-
7.2 COMPANY SHARE ANALYSIS
- 7.2.1 Self-monitoring Blood Glucose Devices
- 7.2.1.1 Abbott Diabetes Care
- 7.2.1.2 LifeScan
- 7.2.1.3 Others
- 7.2.2 Continuous Glucose Monitoring Devices
- 7.2.2.1 Dexcom Inc.
- 7.2.2.2 Medtronic PLC
- 7.2.2.3 Others
- 7.2.3 Insulin Devices
- 7.2.3.1 Omnipod
- 7.2.3.2 Novo Nordisk AS
- 7.2.3.3 Others
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityGermany Diabetes Care Devices Industry Segmentation
Proper management of diabetes involves caring for the overall well-being of the body. As such, assembling a specialized team of healthcare professionals from various fields is crucial. This diabetes care team will collaborate with the patients to create a comprehensive plan for managing their condition and ensuring optimum health while also preventing any potential complications related to diabetes. The German Diabetes Care Devices Market is Segmented into Monitoring Devices (Self-monitoring Blood Glucose (Glucometer Devices, Blood Glucose Test Strips, and Lancets) and Continuous Glucose Monitoring (Sensors and Durables)) and Management Devices (Insulin Pumps (Insulin Pump Device, Insulin Pump Reservoir, ), Insulin Disposable Pens, Insulin Syringes, Cartridges in Reusable Pens, and Jet Injectors). The report offers the value (in USD) and volume (in Units) for the above segments.
| By Device | By Monitoring Devices | Self-monitoring Blood Glucose | Glucometer Devices |
| Blood Glucose Test Strips | |||
| Lancets | |||
| By Device | By Monitoring Devices | Continuous Glucose Monitoring | Sensors |
| Durables | |||
| By Device | By Management Devices | Insulin Pump | Insulin Pump Device |
| Insulin Pump Reservoir | |||
| Infusion Set | |||
| By Device | By Management Devices | Insulin Syringes | |
| Cartridges in Reusable pens | |||
| Insulin Disposable Pens | |||
| Jet Injectors | |||
| By End User | Hospital/Clinics | ||
| Personal/Home |
Germany Diabetes Care Devices Market Research FAQs
How big is the Germany Diabetes Care Devices Market?
The Germany Diabetes Care Devices Market size is expected to reach USD 2.27 billion in 2024 and grow at a CAGR of 6.07% to reach USD 3.05 billion by 2029.
What is the current Germany Diabetes Care Devices Market size?
In 2024, the Germany Diabetes Care Devices Market size is expected to reach USD 2.27 billion.
Who are the key players in Germany Diabetes Care Devices Market?
Abbott Diabetes Care, Roche Diabetes Care, DexCom Inc., Medtronic PLC and Insulet Corporation are the major companies operating in the Germany Diabetes Care Devices Market.
What years does this Germany Diabetes Care Devices Market cover, and what was the market size in 2023?
In 2023, the Germany Diabetes Care Devices Market size was estimated at USD 2.13 billion. The report covers the Germany Diabetes Care Devices Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Germany Diabetes Care Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Germany Diabetes Care Devices Industry Report
Statistics for the 2024 Germany Diabetes Care Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Germany Diabetes Care Devices analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
